We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
-8.67%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.42B
AUM Growth
-$513M
Cap. Flow
+$279M
Cap. Flow %
6.32%
Top 10 Hldgs %
50.32%
Holding
73
New
3
Increased
13
Reduced
2
Closed
14

Top Buys

Rank Stock Value
1
CVAC
CureVac
CVAC
+$107M
2
PCVX icon
Vaxcyte
PCVX
+$60.8M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$53.5M
4
GERN icon
Geron
GERN
+$52.9M
5
PLRX icon
Pliant Therapeutics
PLRX
+$50.2M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$83.8M
2
AKRO
Akero Therapeutics
AKRO
+$52.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25M
4
DALS
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
+$15M
5
CLDX icon
Celldex Therapeutics
CLDX
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELC icon
51
Celcuity
CELC
$4.05B
$14.4M 0.32%
1,400,001
– –
EYPT icon
52
EyePoint Inc
EYPT
$316M
$9.91M 0.22%
3,370,506
– –
CNTB
53
Connect Biopharma Holdings
CNTB
$73.7M
$6.99M 0.16%
6,991,003
– –
BDTX icon
54
Black Diamond Therapeutics
BDTX
$113M
$4.89M 0.11%
2,589,904
– –
WHWK
55
Whitehawk Therapeutics
WHWK
$233M
$4.27M 0.1%
590,218
– –
STSA
56
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$4.13M 0.09%
5,914,252
– –
FUSN
57
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.49M 0.06%
659,992
– –
NAMSW icon
58
NewAmsterdam Pharma Warrant
NAMSW
$52.3M
$613K 0.01%
333,333
– –
ENTX icon
59
Entera Bio
ENTX
$495M
$343K 0.01%
295,966
– –
AKRO
60
DELISTED
Akero Therapeutics
AKRO
– –
-958,980
Closed -$52.6M
LONA
61
LeonaBio Inc
LONA
$68.2M
– –
-188,130
Closed -$5.96M
CVRX icon
62
CVRx
CVRX
$79.9M
– –
-275,000
Closed -$5.05M
DBVT
63
DBV Technologies
DBVT
$739M
– –
-195,896
Closed -$3M
IMUX icon
64
Immunic
IMUX
$141M
– –
-63,218
Closed -$885K
IOBT
65
DELISTED
IO Biotech
IOBT
– –
-1,127,260
Closed -$2.59M
OBIO icon
66
Orchestra BioMed
OBIO
$363M
– –
-610,283
Closed -$6.09M
SCPH
67
DELISTED
scPharmaceuticals
SCPH
– –
-1,856,904
Closed -$13.3M
THRD
68
DELISTED
Third Harmonic Bio
THRD
– –
-534,687
Closed -$2.3M
TVTX icon
69
Travere Therapeutics
TVTX
$5.89B
– –
-3,984,681
Closed -$83.8M
ACHL
70
DELISTED
Achilles Therapeutics
ACHL
– –
-1,607,834
Closed -$1.45M
DALS
71
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
– –
-1,500,000
Closed -$15M
ARYE
72
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
– –
-1,000,000
Closed -$10.1M
CNCE
73
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-1,088,296
Closed -$6.36M
1 2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, RA Capital Management held 73 positions worth $4.42B, down 10% from $4.93B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RA Capital Management deployed $279M of net new capital in Q1 2023, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was CureVac: 12,245,955 shares worth $85.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $25M trimmed.

  • RA Capital Management's largest Q1 2023 buy was CureVac: 12,245,955 shares worth $85.4M.
  • RA Capital Management added most to Vaxcyte in Q1 2023, an estimated $60.8M increase.
  • RA Capital Management's biggest Q1 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $25M.
  • RA Capital Management fully exited Travere Therapeutics in Q1 2023, selling an estimated $83.8M.
  • RA Capital Management's ten largest holdings make up 50% of its $4.42B portfolio in Q1 2023.
  • RA Capital Management opened 3 new positions and closed 14 in Q1 2023.
  • RA Capital Management's portfolio value fell 10% quarter-over-quarter to $4.42B.

Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.